Literature DB >> 20215965

beta-Lactam antibiotic inhibits development of morphine physical dependence in rats.

Scott M Rawls1, David A Baron, Jae Kim.   

Abstract

beta-Lactam antibiotics enhance cellular glutamate uptake. As increased glutamatergic transmission is a primary mediator of opiate dependence, we tested the hypothesis that a beta-lactam antibiotic (ceftriaxone) prevents development of morphine physical dependence in rats. Morphine (20 mg/kg) was injected twice daily for 10 days to induce physical dependence. Naloxone (10 mg/kg) administration 1, 48, and 96 h after the last morphine injection induced a withdrawal syndrome characterized by the appearance of wet-dog shakes, teeth chattering, eye blinking, jumping, and paw tremor. Ceftriaxone (150, 200 mg/kg) injected once daily during chronic morphine exposure inhibited each naloxone-precipitated withdrawal sign. Ceftriaxone efficacy persisted even after the 96 h-naloxone (10 mg/kg) injection. These results suggest that beta-lactam antibiotics inhibit processes leading to development of morphine physical dependence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215965      PMCID: PMC2923426          DOI: 10.1097/FBP.0b013e328337be10

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  17 in total

1.  Inhibition of morphine tolerance and dependence by MS-153, a glutamate transporter activator.

Authors:  T Nakagawa; T Ozawa; K Shige; R Yamamoto; M Minami; M Satoh
Journal:  Eur J Pharmacol       Date:  2001-05-04       Impact factor: 4.432

2.  Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.

Authors:  K A Trujillo; H Akil
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

3.  Localization of neuronal and glial glutamate transporters.

Authors:  J D Rothstein; L Martin; A I Levey; M Dykes-Hoberg; L Jin; D Wu; N Nash; R W Kuncl
Journal:  Neuron       Date:  1994-09       Impact factor: 17.173

4.  Diffusion of ceftriaxone into the cerebrospinal fluid of adults.

Authors:  P H Chandrasekar; K V Rolston; B R Smith; J L LeFrock
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

5.  The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence.

Authors:  P Popik; P Skolnick
Journal:  Pharmacol Biochem Behav       Date:  1996-04       Impact factor: 3.533

6.  The role of AMPA and metabotropic glutamate receptors on morphine withdrawal in infant rats.

Authors:  Hongbo Zhu; Gordon A Barr
Journal:  Int J Dev Neurosci       Date:  2004 Aug-Oct       Impact factor: 2.457

Review 7.  Neural substrates of opiate withdrawal.

Authors:  G F Koob; R Maldonado; L Stinus
Journal:  Trends Neurosci       Date:  1992-05       Impact factor: 13.837

8.  The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.

Authors:  S M Rawls; R Tallarida; W Robinson; M Amin
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 9.  Opiate physical dependence and N-methyl-D-aspartate receptors.

Authors:  Yukihiro Noda; Toshitaka Nabeshima
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

10.  Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence.

Authors:  M E Fundytus; T J Coderre
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more
  19 in total

Review 1.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Synergistic protective role of ceftriaxone and ascorbic acid against subacute diazinon-induced nephrotoxicity in rats.

Authors:  Mohamed M Abdel-Daim
Journal:  Cytotechnology       Date:  2014-08-24       Impact factor: 2.058

3.  Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2.

Authors:  Osama A Abulseoud; Ulas M Camsari; Christina L Ruby; Aimen Kasasbeh; Sun Choi; Doo-Sup Choi
Journal:  Neuropsychopharmacology       Date:  2014-01-23       Impact factor: 7.853

Review 4.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.

Authors:  Kou Takahashi; Joshua B Foster; Chien-Liang Glenn Lin
Journal:  Cell Mol Life Sci       Date:  2015-06-02       Impact factor: 9.261

5.  β-Lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of rats.

Authors:  Bruce A Rasmussen; David A Baron; Jae K Kim; Ellen M Unterwald; Scott M Rawls
Journal:  Amino Acids       Date:  2010-04-13       Impact factor: 3.520

6.  Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator.

Authors:  Ryan A Gregg; Callum Hicks; Sunil U Nayak; Christopher S Tallarida; Paul Nucero; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Neuropharmacology       Date:  2016-04-13       Impact factor: 5.250

7.  Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus.

Authors:  María Carmen Medrano; Aitziber Mendiguren; Joseba Pineda
Journal:  Psychopharmacology (Berl)       Date:  2015-03-20       Impact factor: 4.530

8.  Combined action of MK-801 and ceftriaxone impairs the acquisition and reinstatement of morphine-induced conditioned place preference, and delays morphine extinction in rats.

Authors:  Yaodong Fan; Haichen Niu; Joshua D Rizak; Ling Li; Guimei Wang; Liqi Xu; He Ren; Hao Lei; Hualin Yu
Journal:  Neurosci Bull       Date:  2012-10-03       Impact factor: 5.203

Review 9.  Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.

Authors:  Douglas J Roberts-Wolfe; Peter W Kalivas
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

10.  Functional and morphological characterization of glutamate transporters in the rat locus coeruleus.

Authors:  M C Medrano; I Gerrikagoitia; L Martínez-Millán; A Mendiguren; J Pineda
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.